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Abstract
CGG repeat expansions in FMR1 cause the neurodegenerative disorder Fragile X-associated Tremor/Ataxia
Syndrome (FXTAS). Ubiquitinated neuronal intranuclear inclusions (NIIs) are the neuropathological hallmark of
FXTAS. Both sense strand derived CGG repeats and antisense strand derived CCG repeats support non-AUG
initiated (RAN) translation of homopolymeric proteins in potentially 6 different reading frames. However, the
relative abundance of these proteins in FXTAS brains and their co-localization with each other and NIIs is
lacking. Here we describe rater-blinded assessment of immunohistochemical and immunofluorescence staining
with newly generated antibodies to different CGG RAN translation products in FXTAS and control brains as
well as co-staining with ubiquitin, p62/SQSTM1, and ubiquilin 2. We find that both FMRpolyG and a second
CGG repeat derived RAN translation product, FMRpolyA, accumulate in aggregates in FXTAS brains. FMRpolyG
is a near-obligate component of both ubiquitin-positive and p62-positive NIIs in FXTAS, with occurrence of
aggregates in 20% of all hippocampal neurons and > 90% of all inclusions. A subset of these inclusions also
stain positive for the ALS/FTD associated protein ubiquilin 2. Ubiquitinated inclusions and FMRpolyG+
aggregates are rarer in cortex and cerebellum. Intriguingly, FMRpolyG staining is also visible in control
neuronal nuclei. In contrast to FMRpolyG, staining for FMRpolyA and CCG antisense derived RAN translation
products were less abundant and less frequent components of ubiquitinated inclusions. In conclusion, RAN
translated FMRpolyG is a common component of ubiquitin and p62 positive inclusions in FXTAS patient
brains.
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Introduction
Nucleotide repeat expansions cause more than 40
neurological diseases, including Huntington disease,
C9ORF72-associated Amyotrophic Lateral Sclerosis
and Frontotemporal Dementia, and a number of
spinocerebellar ataxias and myotonic dystrophies [1].
Repeat expansions cause disease through a series of
overlapping mechanisms, including loss of expression
of the repeat containing gene, gain of function
toxicity elicited by repeat RNA, and gain of function
toxicity elicited by proteins generated from AUG ini-
tiated or repeat associated non-AUG initiated (RAN)
translation [2, 3].
Fragile X-associated Tremor/Ataxia Syndrome
(FXTAS) is a neurodegenerative disease caused by a
trinucleotide CGG repeat expansion in the 5′ un-
translated region (UTR) of the FMR1 gene [4]. Clinic-
ally, FXTAS is characterized by intention tremor,
ataxia, gait abnormalities and cognitive decline [5].
Both patients and CGG knock-in (KI) mouse models
of disease have elevated FMR1 mRNA but lower basal
expression of the protein product, FMRP [6, 7]. The
pathologic hallmark of FXTAS is the accumulation of
ubiquitinated neuronal intranuclear inclusions (NIIs)
throughout the brain [8, 9]. NIIs are most prominent
in the hippocampus and, to a lesser degree, in the
frontal cortex and granule cell layer of the cerebellum
[10]. Astrocytic inclusions also occur frequently
within the brainstem and other brain regions [8, 10].
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Despite their clear role in the clinical syndrome and
evidence of cerebellar atrophy on both pathological
analysis and imaging, ubiquitinated inclusions are
relatively rare in cerebellar Purkinje neurons [11].
In initial work in FXTAS, no single dominant protein
species was found in these aggregates [12]. Proteins
identified by mass spectrometry and immunohisto-
chemically include, but are not limited to ubiquitinated
proteins, lamin A/C, αΒ crystallin, a series of histone
proteins and proteasomal subunits, and the RNA bind-
ing proteins Sam68, Muscleblind1, and hnRNPA2/B1
[12–15]. In addition, biotinylated antisense RNA probes
targeting the 5′ UTR, coding region and 3’UTRs of
FMR1 diffusely stained inclusions in nuclei isolated
from FXTAS patient cortex [16]. Based on these initial
findings, it was proposed that CGG repeat RNA serves
as a nidus for inclusion formation by binding to and se-
questering specific proteins into these aggregates. Con-
sistent with this model, many of the factors identified
within inclusions to date are RNA binding proteins
that associate with CGG repeat RNA in in vitro
assays [13–15, 17]. Of note, FMRP itself is not found
in the inclusions and loss of the protein is not associ-
ated with neurodegeneration in clinical cases or ani-
mal models [18, 19].
An alternative mechanism by which inclusions may
form in FXTAS is based on a unique form of protein
translational initiation known as repeat associated non-
AUG (RAN) translation [3, 20]. In rabbit reticulocyte
lysates, transfected cells and neurons, Drosophila, and
mouse models of the disease, expression of the 5′ UTR
of FMR1 leads to RAN translation of a series of homo-
polymeric proteins, with different efficiencies of pro-
duction and accumulation in different reading frames
[21–26]. RAN translation can occur from both sense
strand CGG repeat (producing polyglycine (FMRpo-
lyG), polyalanine (FMRpolyA) and polyarginine
(FMRpolyR) repeat containing proteins) and antisense
strand CCG repeat (producing polyproline (ASFMRpo-
lyP), polyalanine (ASFMRpolyA), and polyarginine
(ASFMRpolyR) containing proteins) mRNA transcripts in
reporter assays [23, 27]. FMRpolyG production in particu-
lar appears critical for NII formation, as mutations that
largely preclude FMRpolyG production in the sequence
just 5′ to the repeat prevents NII formation in Drosophila,
and both CGG KI mice and repeat expressing transgenic
mice [22, 24–26]. Moreover, generation of FMRpolyG ab-
sent the CGG repeat through use of alternative codons is
sufficient to elicit inclusion formation in transfected cells
[28]. Importantly, the ability to generate FMRpolyG is pre-
dictive of whether CGG repeats expressed in neurons,
Drosophila, or in transgenic mice are capable of eliciting
neurodegeneration despite comparable levels of expres-
sion of the repeat containing mRNA [25, 26].
Previous studies have demonstrated the presence of
FMRpolyG positive aggregates in FXTAS patient tissue
using different mouse monoclonal antibodies targeted
against either the N-terminal region or C-terminal re-
gion of FMRpolyG [25, 26, 29, 30]. In addition, ASFMR-
polyP and ASFMRpolyA staining is detected in some
aggregates in FXTAS cases [27]. However, very little
FMRpolyA positive staining has been seen previously
[25]. The relative abundance of each RAN peptide in
FXTAS and their overlap with other pathological
markers of inclusion burden has not been systematically
evaluated to date.
Here we describe a series of new antibodies gener-
ated against FMRpolyG and FMRpolyA epitopes that
contain a portion of the homopolymeric repeat. After
thoroughly establishing the specificity of these anti-
bodies for their pathological targets, we use them to
determine the relative distribution and abundance of
different RAN derived proteins in the brains of
FXTAS patients and their overlap with ubiquitin and
p62 pathology in using blinded analysis to provide
unbiased and rigorous results. These studies suggest
that FMRpolyG, and not FMRpolyA, is a near-
obligate component of NIIs in FXTAS and further
support a role for FMRpolyG accumulation in the
FXTAS pathology.
Materials and methods
FMRpolyG and FMRpolyA polyclonal antibody generation
Rabbit polyclonal antibodies were generated by Abclo-
nal (Cambridge, MA). FMRpolyG peptides were gener-
ated corresponded to either the N-terminal or C-
terminal region of the predicted protein and extended
into the repeat region. The peptide for FMRpolyA also
including a portion of the repeat and the C-terminal
end of the predicted protein. Exact sequences can be
found in Fig. 2 and Fig. 7, respectively. Antibodies were
affinity purified from anti-sera. Pre-bleed sera and the
peptide were used to characterize the antibodies.
Protein concentrations of the pre-bleed sera were
determined. The dilution of pre-bleed sera used had an
equal protein concentration as the dilution of antibody
used. A 100x excess of peptide was incubated with the
antibody prior to use to block the antibodies’ ability to
bind to antigen.
Western blotting
HEK293 cells were transfected with constructs express-
ing FMRpolyG-GFP, ATG-FMRpolyG-GFP, FMRpolyA,
or EGFP-N1 (Clontech) using Fugene HD (Promega)
following the manufacturer’s protocol [24, 26]. Lysates
were collected 24 h after transfection, as previously
described [25, 26, 30]. Proteins were separated using
SDS-PAGE and transferred to PVDF membrane.
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Proteins were detected with antibodies against GFP
(Sigma, 1:1000) and FMR polyclonal antibodies (11000).
GAPDH or tubulin was used as a loading control.
Immunocytochemistry
HEK293 cells were grown on a 4-well chamber slide and
transfected with FMRpolyG-GFP, ATG-FMRpolyG-GFP,
FMRpolyA-GFP, or EGFP-N1 using Fugene HD [24, 26].
Cells were fixed with 4% paraformaldehyde 24 h after
transfection and permeabilized with 0.1% Triton X-100
in phosphate buffered saline, 10 mM MgCl2, 1 mM
CaCl2 (PBS-MC). 5% normal goat serum in PBS-MC
(0.1% Triton) was used as a blocking agent and diluent
for primary antibodies. N-terminal FMRpolyG (NTF1, 1:
200), C-terminal FMRpolyG, (CTF1, 1:100), and FMRpo-
lyA (1:100) were incubated with anti-GFP (1:1000) over-
night at 4 °C. AlexaFluor488 goat anti-mouse and
AlexaFluor555 goat anti-rabbit IgG secondary antibodies
were used. Nuclei were stained and coverslips mounted
using Prolong Gold with DAPI (ThermoFisher). Images
were captured on an inverted Olympus (Tokyo, Japan)
IX71 microscope at the same exposure and processed
using SlideBook 5.5 software.
Autopsy tissue sources
Control, C9ORF72, SCA3 and FXTAS brain regions
were obtained from the University of Michigan Brain
Bank, the New York Brain Bank, and the McKnight
Brain Institute Brain bank at the University of Florida
with informed consent of the patients or their rela-
tives and the approval of the local institutional review
boards. FXTAS cases 1–3 were described previously
[26, 27]. Case #4 is the subject of a separate manu-
script in review (Benoit Giasson, Anthony Yachnis,
and Stefan Prokop, personal communication). This
case had disease onset at age of 55 and death at age
69 in a male with 96 CGG repeats.
Immunohistochemistry and co-immunofluorescence
For immunohistochemistry, paraffin embedded sec-
tions were de-paraffinized with a series of xylene
washes and decreasing concentrations of ethanol.
Antigen retrieval (AR) was done with citrate buffer, if
necessary. Endogenous peroxidase was quenched with
1% hydrogen peroxide for 30 min. Sections were
blocked in 5% normal goat serum (NGS) in Tris, pH
7.6. Primary antibodies, p62 (Proteintech, 1:1000, acid
AR), ubiquitin (DAKO, 1:250, basic AR), ubiquilin 2
(Novus Biologicals, 1:200, acid AR), NTF1 (Abclonal,
1:200, no AR), CTF1 (Abclonal, 1:40, basic AR), and
FMRpolyA (Abclonal, 1:100, basic AR), 8FM (Sigma,
1:50), 9FM (Sigma, 1:50), were diluted in 5% NGS
Tris B (Tris pH 7.6, 0.1% Triton-X 100, 0.5% bovine
serum albumin) and were incubated with sections
overnight at 4 °C. The following day, sections were
washed in Tris A (Tris pH 7.6, 0.1% Triton) and Tris
B. Antibody detection was determined using VEC-
TASTAIN Elite ABC HRP kit (Vector Laboratories)
following the manufacturer’s protocol. Sections were
counterstained with hematoxylin (Vector Laborator-
ies). After dehydrating the slides through a series of
increasing concentration of ethanol and then xylenes,
coverslips were mounted to the slides using DPX
mounting media. Images were taken on an Olympus
BX51 microscope.
For co-immunofluorescence, sections were blocked
with 5% NGS in PBS-MC. Ubiquitin, ubiquilin 2, p62,
NTF1, CTF1, and FMRpolyA were diluted in 5% NGS-
PBS-MC, overnight at 4 °C. Goat anti-rabbit and goat
anti-mouse IgG antibodies conjugated to Alexa-
Fluor488 or AlexaFluor635 (ThermoFisher, 1:500) were
used. Nuclei were stained and coverslips mounted using
Prolong Gold with DAPI (ThermoFisher). Images were
taken on an Olympus confocal microscope and com-
piled and analyzed using ImageJ.
Analysis of immunohistochemistry
Intensity of staining was graded on a five-point inte-
gral scale of 0 (no staining) to 3 (intense staining
with an additional point added if an aggregate/inclu-
sion was present. Grading was done by three separate
reviewers blinded to the genotype of the tissue as well
as the identity of the antibody being used. All
reviewers were trained and tested to ensure consistent
grading for intensities and inclusion identification. A
subset of images was repeated among reviewers to
assess variability during retest. All images were
randomized and anonymized prior to assigning them
to the reviewers. An average of 20 images per slide
was counted for each of the control and FXTAS cases
and multiple brain regions were analyzed. As the
presence of more than one inclusion per cell was not
observed, the number of cells with inclusions were
presented as a ratio to the total number of cells of
that class in the images evaluated.
A summary of the histology scoring can be found in
Table 1. A plus/minus grading scale was used based on
the percentage of cells that had a significant amount of
staining. If fewer than 1% of cells had significant stain-
ing, this was called negative. Low intensity staining had
up to 10% of cell stained, moderate intensity up to 20%,
high intensity up to 30%, and highly intense and
frequent up to 30% and were graded +, ++, +++, and
++++, respectively. To determine the relative distribu-
tion of inclusions between glia and neurons, the total
number of observed inclusions were separated into glial
or neuronal using standard morphological criteria [10].
Neurons were identified by their size, their large
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centrally placed nuclei with dense heterochromatin and
nucleoli, and by their abundant cytoplasm. In contrast,
astrocytes, which included oligodendroglia, were identi-
fied by their smaller, euchromatic irregular, ovoid
nuclei without nucleoli or abundant cytoplasm. Excep-
tions to this strategy were made for granule cells in the
cerebellum and near the edges of samples, where endo-
cytic cells might complicate this interpretation.
Statistical analysis
Tabulated scores of the percentage of cells containing
an aggregate as well as the staining intensity score were
analyzed using a Mann-Whitney U two-tailed t-test
with Bonferroni correction for multiple comparisons
where appropriate. The Co-localization of immuno-
fluorescence signal within inclusions was analyzed
using a Chi-Squared test with Yates correction. All
statistical analyses were conducted using GraphPad
Prism software.
Results
Ubiquitin, p62/SQSTM1, and ubiquilin 2 (UBQLN2)
are components of intracellular inclusions in a num-
ber of neurodegenerative diseases, including Hunting-
ton disease and C9ORF72-associated ALS/FTD. In
non-disease brain, these proteins are generally diffuse
within neurons when visualized by immunohistochem-
istry in both the hippocampus and cortex (Fig. 1a, e
and i). Consistent with the original pathological
description of FXTAS, we observed significant ubiqui-
tin pathology in FXTAS cases compared to controls
(Fig. 1b-d), with intranuclear inclusions observed
throughout the hippocampus and cortex, but with
relatively fewer inclusions in the brainstem and cere-
bellum. Aggregates in FXTAS also stained positive for
p62 (Fig. 1e-g), consistent with a recent report [31].
We also observed UBQLN2 positive inclusions in
FXTAS neuronal nuclei (Fig. 1i-k). Inclusions outside
of the nucleus within the neuropil were very rare for
all three markers of aggregation.
To quantify the relative accumulation and intensity
of staining for these three proteins in FXTAS, we
performed quantification of staining for each marker
in both FXTAS and control samples from the hippo-
campus and cortex. Quantification was done by raters
who were blinded to the genotype of the case being
stained to enhance the rigor of the analysis. A large
fraction of FXTAS hippocampal neurons contained
inclusions, with ubiquitin, p62, or UBQLN2 aggre-
gates present in 25, 20%, or 8%, of neurons (> 300)
counted in each of 4 FXTAS cases, respectively
(Fig. 1b, f, and j). This was significantly higher than
controls. Inclusions were present in both glia and
neurons for all three proteins (Fig. 1c, g, k). Gener-
ally, a higher percentage of control neurons have no
staining with any of these antibodies. The average
staining intensity for each antibody was significantly
higher in FXTAS tissue compared to control tissue
(Fig. 1d, h, l). Results are summarized in Table 1.
To better characterize the role of RAN translation
products in FXTAS, we generated a series of new poly-
clonal antibodies against FMRpolyG and FMRpolyA.
Three previously published mouse monoclonal FMRpo-
lyG antibodies were generated using epitopes just N-
Table 1 Summary of antibody staining in control and FXTAS patient tissue
Brain Region Case Age Sex UB p62 UBQLN2 Nterminal FMRpolyG Cterminal FMRpolyG
Hippocampus Control 1 59 N/A ++ + ++ + +
2 71 M + – + – –
3 39 M – + – – –
4 47 M – + + – –
FXTAS 1 74 M ++++ ++++ +++ ++++ +
2 78 M +++ ++ ++++ ++++ +
3 80 M ++++ ++ + ++ ++
4 69 M ++++ +++ ++ ++ ++
Cortex Control 2 71 M + – – – –
4 47 M + + + + –
5 84 M ++++ – – +++ –
6 78 M ++++ – – ++++ –
FXTAS 1 74 M ++++ ++ + ++++ +
2 78 M ++ ++ – ++++ +
3 80 M ++++ + + + –
-, negative; +, low-intensity staining; ++, moderate-intensity staining; +++, high-intensity staining; ++++, high-intensity and frequent staining. UBQLN2 ubiquilin 2,
N/A not available; M, male
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Fig. 1 (See legend on next page.)
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terminal (8FM) or C-terminal (9FM and 2 J7) to the re-
peat element. Qualitative analysis in 2 FXTAS cases with
2 J7 estimated that ~ 30% of the inclusions in FXTAS
stained positive for FMRpolyG [26]. However, it was un-
clear whether the remaining inclusions were the result
of alternative RAN translation proteins, repeat RNA trig-
gered aggregates, or epitope masking that precluded rec-
ognition by the FMRpolyG antibody. Consistent with the
latter concept, the N-terminal antibody had greater
staining in FXTAS cases [2]. We therefore used larger
epitopes involving the N-terminal region (NTF1) and C-
terminal region (CTF1) of FMRpolyG, under the as-
sumption that some parts of the protein might be
subject to proteolytic cleavage. The exact epitopes
used are shown in Fig. 2a, underlined in red. A
unique feature of the NTF1 and CTF1 was that each
epitope also included a portion of the polyglycine re-
peat. Western blot analysis of HEK293 cell lysates ex-
pressing either EGFP-N1 or FMRpolyG fused to GFP
showed both CTF1 and NTF1 antibodies specifically
recognized FMRpolyG (Fig. 2b, d). NTF1 had some
nonspecific staining compared to CTF1 by immuno-
blot. By immunofluorescence, both antibodies recog-
nized cells expressing FMRpolyG (Fig. 2c, e).
To validate the specificity of these antibodies, we per-
formed a number of additional controls. A potential
problem with polyclonal antibodies, in particular, is
non-specific binding of the antibody to proteins not
containing the antigen. The specificity can be deter-
mined by incubating the antibody with a peptide bear-
ing the recognition sequence of the antibody. The
antibody would bind the peptide and would not be able
to bind the antigen in either protein lysates or human
tissue. After incubating both NTF1 and CTF1 with
their respective peptides, neither antibody recognized
either FMRpolyG containing lysates (Fig. 3a, d) or
FXTAS tissue (Fig. 3b, e). Pre-immune sera for CTF1
had no staining in control or FXTAS hippocampal tis-
sue (Fig. 3c) while pre-immune sera for NTF1 had light
cytoplasmic staining in both control and FXTAS tissue
(Fig. 3f).
With the newly validated antibodies, we looked to
see if they could recognize FMRpolyG in patient
FXTAS brain tissue. In hippocampal and cortical neu-
rons, CTF1 exhibited substantial cytoplasmic staining
in both control and FXTAS tissue (Fig. 4a, e). CTF1
positive inclusions were relatively rare, with approxi-
mately 3 and 1.2% of FXTAS neurons exhibiting
CTF1 positive aggregates in the hippocampus and
cortex, respectively, by blinded quantification (Fig. 4b,
f). This was significantly greater than that observed in
control tissues. The overall intensity of staining was
significantly higher in FXTAS cortex and hippocam-
pus compared to control (Fig. 4d, h). Most CTF posi-
tive inclusions were in neurons (Fig. 4c, g).
In contrast to the CTF1 antibody, NTF1 staining of
FMRpolyG was qualitatively different. Staining of hip-
pocampal and cortical neurons with NTF1 showed
low levels of cytoplasmic staining in control tissue.
However, in some control cases, cortical neurons had
moderate diffuse nuclear staining without aggregate
formation. In FXTAS cases, NTF1 avidly stained
intranuclear FMRpolyG positive aggregates in both
the hippocampus and cortex (Fig. 5a, e). The percent-
age of neurons with FMRpolyG NTF1 positive aggre-
gates (17%) was similar to the percentages seen with
ubiquitin (25%) and p62 (21%) and was significantly
higher than control tissue (Fig. 5b). In the cortex,
fewer total neurons had aggregates but the percentage
of neurons with FMRpolyG aggregates in FXTAS
cases was comparable to staining with Ubiquitin and
p62 and much greater than control cases (Fig. 5f).
(See figure on previous page.)
Fig. 1 Staining for pathological markers Ubiquitin, p62, and UBQLN2 in FXTAS brain. a Representative images from control (left) and FXTAS (right)
hippocampus (upper panels) and cortex (lower panels) stained for ubiquitin. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar =
20 μm. b Quantification of a represented as percent neurons with aggregates. Data from hippocampus (top) and cortex (bottom). Results expressed as
means ± SEM; Mann-Whitney U-test **** p < 0.0001. c Graph showing the percentage of cells with ubiquitin positive aggregates that are neurons and
glia in hippocampus (top) and cortex (bottom) in FXTAS tissue. d Graph comparing the average staining intensity for ubiquitin in hippocampus (top)
and cortex (bottom) between control and FXTAS tissue. Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001. e Representative
images from control (left) and FXTAS (right) hippocampus (upper panels) and cortex (lower panels) stained for p62. Nuclei stained with hematoxylin.
Inset- 60x magnification. Scale bar = 20 μm. f Quantification of e represented as percent neurons with aggregates. Data from hippocampus (top) and
cortex (bottom). Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001. g Graph showing the percentage of cells with p62 positive
aggregates that are neurons and glia in hippocampus (top) and cortex (bottom) in FXTAS tissue. h Graph comparing average staining intensity for p62
in hippocampus (top) and cortex (bottom) between control and FXTAS tissue. Results expressed as means ± SEM; Mann-Whitney U-test **** p <
0.0001. i Representative images from control (left) and FXTAS (right) hippocampus (upper panels) and cortex (lower panels) stained for UBQLN2. Nuclei
stained with hematoxylin. Inset-60x. Scale bar = 20 μm. j Quantification of i represented as percent of neurons with aggregates. Data from
hippocampus (top) and cortex (bottom). Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001, ns = not significant. k Graph
showing the percentage of cells with UBQLN2 positive aggregates that are neurons or glia in hippocampus (top) and cortex (bottom) from FXTAS
tissue. l Graph comparing average staining intensity for UBQLN2 in hippocampus (top) and cortex (bottom) between control and FXTAS tissue. Results
expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001
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Quantification of the average staining intensity in
FXTAS cortex and hippocampus was significantly
higher than in controls by analysis performed blinded
to genotype and antibody evaluated (Fig. 5d, h). A
majority of NTF1 positive inclusions were found in
glia in the cortex and hippocampus (Fig. 5c, g).
To confirm the specificity of NTF1 for FMRpolyG, this
antibody was also used to stain tissue from the pons of
one SCA3 patient and from the cerebellum of two
C9ORF72 repeat expansion cases who had ALS/FTD.
The pons is a region of the brain known to have ubiqui-
tinated aggregates in SCA3 [32]. Moreover, dipeptide re-
peat proteins accumulate in large ubiquitin and p62
positive inclusions in the cerebellum of most cases with
C9ORF72 repeat expansions [33, 34]. When this region
was stained with NTF1, nuclear aggregates were not
Fig. 2 Generation and characterization of new FMRpolyG antibodies. a Schematic showing epitopes for published (8FM, 9FM and 2 J7) and novel
(NTF1, N-terminal FMRpolyG and CTF1, C-terminal FMRpolyG) antibodies against FMRpolyG. Epitope sequence is underlined (green line - 8FM and
9FM, blue line- 2 J7, red line - NTF1 and CTF1 FMRpolyG antibodies used in this paper). b Western blot using CTF1 and GFP antibodies in HEK293
cells transfected with a non-template control (NTC- lanes 1), EGFP-N1 plasmid (lanes 2), FMRpolyG100GFP (lanes 3) and ATG FMRpolyG99GFP (lanes
4). GAPDH used as loading control. c Immunocytochemistry of Mock, EGFP-N1 and ATG FMRpolyG100GFP transfected HEK293 cells using CTF1
antibody. Nuclei stained using DAPI. Scale in C = 10 μm. d Western blot using NTF1 and GFP antibodies in HEK293 cells transfected with a non-
template control (NTC- lanes1), EGFP-N1 plasmid (lanes 2), FMRpolyG100GFP (lanes 3) and ATG FMRpolyG99GFP (lanes 4). GAPDH used as loading
control. e Immunocytochemistry of Mock, EGFP-N1 and ATG FMRpolyG100GFP transfected HEK293 cells using NTF1 antibody. Nuclei stained using
DAPI. Scale in E = 10 μm
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Fig. 3 Validation of new FMRpolyG antibodies on FXTAS brain tissue. a Western blot using GFP and CTF1 with and without blocking peptide in
HEK293 cells that were either mock transfected (lanes1) or transfected with EGFP-N1 plasmid (lanes 2), FMRpolyG 100GFP (lanes 3) and ATG
FMRpolyG99GFP (lanes 4). Tubulin used as loading control. b Representative brain images from FXTAS patients stained using CTF1 antibody with
and without blocking peptide at 4x (top), 20x (middle) and 60x (bottom) magnification. Nuclei stained with hematoxylin. Scale bars are 500 μm,
100 μm and 20 μm respectively. c Staining of control and FXTAS brain tissue using pre-bleed serum from CTF1 antibody production. Nuclei
stained with hematoxylin. Scale bar = 20 μm. d Western blot using GFP and NTF1 with and without blocking peptide in HEK293 cells that were
either mock transfected (lanes1) or transfected with EGFP-N1 plasmid (lanes 2) and FMRpolyG100GFP (lanes 3). Tubulin used as loading control. e
Representative brain images from FXTAS patients stained using NTF1 antibody with and without blocking peptide at 4x (top), 20x (middle) and
60x (bottom) magnification. Nuclei stained with hematoxylin. Scale bars are 500 μm, 100 μm and 20 μm respectively. f Staining of control and
FXTAS brain tissue using pre-bleed serum from NTF1 antibody production. Nuclei stained with hematoxylin. Scale bar = 20 μm
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observed in SCA3 patient tissue or C9ORF2 tissue, des-
pite the detection of such inclusions by anti-ubiquitin
antibodies (Fig. 5i, j).
Another protein generated by RAN translation from
reporter constructs is FMRpolyA [23, 24, 26]. As with
FMRpolyG, the contribution of FMRpolyA to FXTAS
pathology was determined. A polyclonal antibody was
generated against the C-terminal fragment of
FMRpolyA (Fig. 6a). By western blot and immuno-
cytochemical analysis, the antibody specifically recog-
nized FMRpolyA in transfected HEK293 cells (Fig. 6b,
c). Incubating the antibody against FMRpolyA with
the corresponding peptide prevented the antibody
from recognizing FMRpolyA in HEK293 lysates or in
human brain tissue (Fig. 6b, d). The pre-immune
serum has some light cytoplasmic staining in control
Fig. 4 C-terminal targeted FMRpolyG antibody staining in FXTAS tissue. a Representative images from control (left) and FXTAS (right)
hippocampus stained with CTF1 antibody. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar = 20 μm. b Quantification of
a represented as percent neurons with CTF1 positive aggregates in hippocampus. Results expressed as means ± SEM; Mann-Whitney U-
test **** p < 0.0001. c Graph showing the percentage of cells with CTF1 positive aggregates that are neurons or glia in FXTAS
hippocampus. d Graph comparing average staining intensity for CTF1 positive aggregates between control and FXTAS hippocampus.
Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001. e Representative images from control (left) and FXTAS (right)
cortex stained for CTF1 positive aggregates. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar = 20 μm. f Quantification
of e represented as percent neurons with aggregates in cortex. Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001.
g Graph showing the percentage of cells with CTF1 positive aggregates that are neurons or glia in FXTAS cortex. h Graph comparing
average staining intensity for CTF1 positive aggregates between control and FXTAS cortex. Results expressed as means ± SEM; Mann-
Whitney U-test **** p < 0.0001
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and FXTAS patient tissue but aggregates were not
seen (Fig. 6e).
FMRpolyA exhibited light cytoplasmic staining in
both control and FXTAS tissue. FMRpolyA positive
intranuclear aggregates were rare in hippocampal neu-
rons (1.5%) but were observed significantly more fre-
quently in FXTAS cases compared to controls. In
contrast, intranuclear inclusions were not observed at
an increased frequency in FXTAS compared to con-
trol cortical neurons by rated blinded assessment
(Fig. 6f, g). The average staining intensity was actually
decreased in FXTAS tissue compared to control tissue
(Fig. 6h). These data, along with previous published
findings [25], suggest FMRpolyA is not a major com-
ponent of intranuclear inclusions in FXTAS.
Neurodegeneration of the cerebellum is a common
feature in FXTAS cases. We therefore used these
antibodies on patient cerebellar tissue (Fig. 7) In
FXTAS, ubiquitin, p62, and NTF1 stained aggregates
throughout the granular layer of the cerebellum
(Fig. 7b). Rare aggregates were seen in Purkinje cells
with ubiquitin and NTF1 (Fig. 7c), but these were less
abundant than staining observed in the granule cell
layer, a finding largely consistent with published
studies.
To see if these antibodies are staining the same ag-
gregates, co-immunofluorescence was performed.
NTF1 and CTF1 stain the same aggregates as previ-
ously published antibodies 9FM and 8FM, respect-
ively, although the intensity of staining and sensitivity
for detection of inclusions were greater for NTF1 in
particular (Additional file 1). In FXTAS hippocampal
neurons, ubiquitin positive aggregates were also posi-
tive for p62, UBQLN2, NTF1, CTF1, FMRpolyA as
well as ASFMRpolyP and ASFMRpolyA at ratios
greater than expected by chance, even after correction
for multiple comparisons (Fig. 8a-c, n > 50 inclusions/
comparison). Nearly all ubiquitin aggregates also
stained positive for p62 and FMRpolyG with NTF1
whereas only 58 and 20% were positive for UBQLN2
or FMRpolyA, respectively (Fig. 8b, c). Intriguingly,
14% of p62+ and 11% of NTF1+ inclusions were
negative for ubiquitin (Fig. 8c, black bars). Consistent
with this, p62 co-localized to the same aggregates as
NTF1 and CTF1 (Fig. 8d). In contrast, only 42% of
NTF1 inclusions were UBQLN2 +, although effect-
ively all UBQLN+ inclusions also stained with NTF1
(Fig. 8e).
Discussion
FXTAS is an under-recognized inherited neurodegen-
erative condition which lacks effective therapeutic
options [4]. Accurately defining the pathology in
patients provides insight into how transcribed CGG
repeat expansions elicit toxicity and drive neuronal
death. Here we have evaluated a series of pathological
markers predominantly in the hippocampus, cortex
and cerebellum of FXTAS cases compared to controls
in a rater-blinded fashion. These studies reveal that
p62 and ubiquitin positive inclusions are present in a
large percentage of neurons, with the greatest burden
observed in pyramidal hippocampal neurons, consist-
ent with past studies [8, 10, 31]. We find that
FMRpolyG is detectable in the vast majority of these
inclusions and in ~ 20% of all hippocampal neurons
overall in FXTAS patients. In contrast, other RAN
translation proteins generated from FMR1 and
ASFMR1 mRNA are detectable in a much lower per-
cent of inclusions, as is the ALS and autophagy-
associated protein UBQLN2. In the context of pub-
lished studies demonstrating that FMRpolyG is the
most abundantly translated RAN protein from CGG
repeats and that production of FMRpolyG is required
for inclusion formation in Drosophila, transfected
(See figure on previous page.)
Fig. 5 N-terminal targeted FMRpolyG antibody staining in FXTAS tissue. a Representative images from control (left) and FXTAS (right)
hippocampus stained with NTF1 antibody. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar = 20 μm. b Quantification
of a represented as percent neurons with NTF1 positive aggregates in hippocampus. Results expressed as means ± SEM; Mann-Whitney
U-test **** p < 0.0001. c Graph showing the percentage of cells with NTF1 positive aggregates that are neurons or glia in FXTAS
hippocampus. d Graph comparing average staining intensity for NTF1 positive aggregates between control and FXTAS hippocampus.
Results expressed as means ± SEM; Mann-Whitney U-test **** p < 0.0001. e Representative images from control (left) and FXTAS (right)
cortex stained with NTF1 antibody. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar = 20 μm. f Quantification of E
represented as percent neurons with NTF1 positive aggregates in cortex. Results expressed as means ± SEM; Mann-Whitney U-test ****
p < 0.0001. g Graph showing the percentage of cells with NTF1 positive aggregates that are neurons or glia in FXTAS cortex. h Graph
comparing average staining intensity for NTF1 positive aggregates between control and FXTAS cortex. Results expressed as means ± SEM;
Mann-Whitney U-test **** p < 0.0001. I Representative images showing UB & NTF1 staining of control, SCA3, C9ORF72/ALS-FTD and FXTAS
brain. Nuclei stained with hematoxylin. Scale bars = 20 μm. j Quantification of i showing percent neurons with UB and NTF1 positive
aggregates in control, FXTAS, C9ORF72/ALS-FTD and SCA3 tissues. Results expressed as means ± SEM; Mann-Whitney U-test
**** p < 0.0001
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cells and both CGG KI and CGG transgenic mice
[22, 25, 26], these data are consistent with a disease
model where FMRpolyG production is a central con-
tributor to ubiquitinated neuronal intranuclear inclu-
sion formation in FXTAS.
We used two new polyclonal antibodies to FMRpo-
lyG directed to the N-terminus (NTF1) and the C-
terminus (CTF1) of the protein. Intriguingly, these
two antibodies did not have the same patterns of
staining. Specifically, NTF1 had diffuse nuclear stain-
ing in control cortex and hippocampus and robustly
stained inclusions throughout the brain. In contrast,
CTF1 had mild staining predominantly in the cyto-
plasm in control cases and stained inclusions in a
lower fraction of neurons in FXTAS cases. The cause
of this discrepancy is not yet known. Control studies
using pre-immune sera or pre-treatment with a block-
ing peptide demonstrate that staining by both anti-
bodies is specific to their epitopes. Moreover, NTF1
does not stain ubiquitinated inclusions in two differ-
ent neurodegenerative disease cases, SCA3 and
C9ORF72 associated ALS/FTD. In addition, both epi-
topes are unique within the proteome and fragments
of their epitopes do not clearly overlap with other
proteins. These differences could reflect different af-
finities of the antibodies for their epitope targets. Ar-
guing against this hypothesis is the finding that these
staining patterns appear consistent with previously
published antibodies, where monoclonal FMRpolyG
C-terminal targeted antibodies have lower staining of
inclusions and a diffuse cytoplasmic pattern in
FXTAS tissues while the N-terminal targeted antibody
more robustly stained inclusions [17, 26, 29]. Access
to the indicated epitopes in tissue may be different
due to protein interactions or characteristics of the
inclusions formed. Alternatively, FMRpolyG may
undergo proteolytic cleavage in cells into smaller frag-
ments that remove the C-terminal component of the
protein and leave an N-terminal fragment consisting
mostly of the polyglycine expansion fragment. Of
note, this polyglycine component is critical for inclu-
sion formation in overexpression systems [25, 26, 28].
When the 5’UTR of FMR1 is placed upstream of
GFP or nanoluciferase and expressed from plasmids
or in vitro transcribed mRNA, FMRpolyG production
occurs at both normal and expanded CGG repeat
sizes in the absence of an AUG codon, suggesting
that the protein could be made normally from FMR1
mRNA [23, 25, 26]. Consistent with this hypothesis,
we observe that both NTF1 and CTF1 have some
staining in control cortical and hippocampal neurons.
Whether FMRpolyG produced from normal sized re-
peats has a function is unknown. Previous work sug-
gests that FMRpolyG interacts with a variety of
proteins, including the nuclear lamin associated factor
LAP2β [25]. However, the interactome of this protein
was defined in the setting of fusion of FMRpolyG to
GFP with an expanded CGG repeat and with overex-
pression in HEK293 cells. As such, the relevance of
these interactors to the native repeat size in human
neurons or brain is not clear. Future studies will be
needed to define what, if any, functions and interac-
tions FMRpolyG has in neurons under normal
contexts.
We also describe a new antibody raised against
FMRpolyA. This protein is made less efficiently than
FMRpolyG in RAN translation reporter assays and its
production is much more dependent on an expanded
CGG repeat [23]. Moreover, it is significantly less ag-
gregation prone than FMRpolyG in GFP fusion stud-
ies in transfected cells [26]. Consistent with these
features, we observe very little FMRpolyA in control
or FXTAS brains and only a small percentage of in-
clusions stain positive for FMRpolyA. The staining
observed is equivalent to or less than that observed
even for RAN translation products generated from
(See figure on previous page.)
Fig. 6 FMRpolyA staining in control and FXTAS tissues. a Protein sequence of FMRpolyA epitope. b Western blot using FMRpolyA
antibody with and without blocking peptide and GFP in HEK293 cells that were either mock transfected (lanes1), transfected with EGFP-
N1 plasmid (lanes 2) and ATG FMRpolyA100 GFP (lanes 3). GAPDH used as a loading control. c Immunocytochemistry of Mock, EGFP-N1
and FMRpolyA100GFP transfected HEK cells using FMRpolyA antibody. Nuclei stained using DAPI. Scale bar is = 10 μm. d Representative
brain images from FXTAS patients stained using FMRpolyA antibody with and without blocking peptide at 4x (top), 20x (middle) and 60x
(bottom) magnification. Nuclei stained with hematoxylin. Scale bars are 500 μm, 100 μm and 20 μm respectively. e Staining of control and
FXTAS brain tissue using pre-bleed serum from FMRpolyA antibody production. Nuclei stained with hematoxylin. Scale bar = 20 μm. f
Representative images from control (left) and FXTAS (right) hippocampus (upper panels) and cortex (lower panels) stained with FMRpolyA
antibody. Nuclei stained with hematoxylin. Inset- 60x magnification. Scale bar = 20 μm. g Quantification of F represented as percent
neurons with aggregates. Data from hippocampus (top) and cortex (bottom). Results expressed as means ± SEM; Mann-Whitney U-test
**** p < 0.0001. h Graph showing the percentage of cells with FMRpolyA positive aggregates that are neurons or glia in hippocampus
(top) and cortex (bottom) from FXTAS tissue. i Graph comparing average staining intensity for FMRpolyA between control and FXTAS
hippocampus (top) and cortex (bottom). Mann-Whitney U-test * p < 0.05, ns = not significant
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ASFMR1 [27], whose transcript is produced at a
significantly lower abundance that FMR1 in both
patients and controls. These findings are consistent
with a prior study suggesting FMRpolyA is not readily
observed in most FXTAS inclusions [25]. While these
studies do not rule out a role for FMRpolyA in
disease pathogenesis, they do suggest that it is not a
central nucleator or major component of ubiquiti-
nated inclusions in FXTAS.
This study has some limitations. Due to tissue ac-
cess issues, we could not evaluate all of the anti-
bodies described across all brain tissues and regions.
In addition, the study used a relatively small cohort
of cases and controls. As such, the generalizability of
the findings to other FXTAS cases and premutation
carriers may be limited. In addition, the ideal control
tissue for these studies would have been brain sam-
ples from a fully methylated Fragile X Syndrome
Fig. 7 Cerebellar staining for FMRpolyG and other pathological markers. a Representative 20x images of cerebellum stained with the
indicated antibodies from control and FXTAS brain tissues. Scale bar is 100 μm. b Representative 60x images from the granular cell layer
of control and FXTAS patients stained with the indicated antibodies. Scale bar = 20 μm. c Representative 60x images from the Purkinje
cell layer of control and FXTAS patients stained with the indicated antibodies. Scale bar = 20 μm
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patient, as such a patient would presumably produce
no FMR1 or ASFMR1 mRNA. However, such cases
are rare and were not available to us. As such, a po-
tential component of non-specific staining for
FMRpolyG in control human brains in particular can-
not be ruled out.
In summary, this study describes three new anti-
bodies raised against epitopes from RAN translation
products generated from CGG repeat expansions in
FMR1 mRNA. They confirm that FMRpolyG is a
prominent component of ubiquitinated inclusions in
FXTAS. These new antibodies will be a valuable
Fig. 8 Co-localization of FMR antibodies. a Immunofluorescence in control and FXTAS brain tissue co-stained with UB and p62 (left
panels) and UB and UBQLN2 (right panels). Nuclei were stained with DAPI. Scale bar = 10 μm. b Immunofluorescence in control and
FXTAS brain tissue co-stained with UB and either CTF1, NTF1, FMRpolyA, ASFMRpolyP or ASFMRpolyA. Nuclei were stained with DAPI.
Scale bar = 10 μm. c Graph comparing the percent of inclusions that were either UB positive and co-stain negative, UB negative and
co-stain positive, or both UB positive and co-stain positive. Chi-squared test with Bonferroni Correction for multiple comparisons. N >
50 inclusions/comparison. **** p < 0.0001. d Immunofluorescence in control and FXTAS brain tissue co-stained with p62 and CTF1 (left
panels) and p62 and NTF1 (middle panels). Nuclei were stained with DAPI. Scale bar = 10 μm. Graph comparing the percent of
inclusions that were either p62 positive and CTF1/NTF1 negative, UB negative and CTF1/NTF1 positive, or UB positive and CTF1/NTF1
positive (right). Chi-squared test with Bonferroni correction for multiple comparisons. N > 50cells/comparison. **** p < 0.0001. e
Immunofluorescence in control and FXTAS brain tissue co-stained with NTF1 and UBQLN2. Nuclei were stained with DAPI. Scale bar =
10 μm. Graph comparing the percent of inclusions positive for NTF1 and UBQLN2 (right). Chi-squared test with Bonferroni correction.
**** p < 0.0001
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resource to the research community and extend pre-
vious studies suggesting a role for RAN translation in
the pathogenesis of FXTAS and other nucleotide re-
peat expansion disorders.
Additional file
Additional file 1 Co-localization of N-terminal and C-terminal FMRpolyG
antibodies. A Immunofluorescence in control and FXTAS brain tissue
stained with CTF1 and 9FM antibody (left). Nuclei were stained with DAPI.
Scale bar = 10 μm. Graph comparing the percent of inclusions positive for
CTF1 and 9FM (right). Chi-squared test. **** p < 0.0001. B Immunofluores-
cence in control and FXTAS brain tissue stained with NTF1 and 8FM anti-
body (left). Nuclei were stained with DAPI. Scale bar = 10 μm. Graph
comparing the percent of inclusions positive for NTF1 and 8FM (right).
Chi-squared test. **** p < 0.0001.
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